Wednesday, July 8, 2026

Patent intelligence · US

US 11357777

Use of sGC stimulators for the treatment of nonalcoholic steatohepatitis (NASH)

granted A61KA61K31/197A61K31/198A61K31/4985
Status granted
Linked drugs 1
Pipeline programs 6
Years to expiry 16
Applicant portfolio 17
Related coverage 1
Patent details — US 11357777

Quick answer

US 11357777 (Use of sGC stimulators for the treatment of nonalcoholic steatohepatitis (NASH)) is held by Cyclerion Therapeutics, Inc.. Status: granted. Granted Jun 14, 2022. Expires Jun 9, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
23
CPC classes
A61K, A61K31/197, A61K31/198, A61K31/4985, A61K31/506, A61K31/519

More from Cyclerion Therapeutics, Inc.

Related pharmaceutical patents in our USPTO index.

  1. US 12247025

    Processes for preparation of soluble guanylate cyclase stimulators

    Cyclerion Therapeutics, Inc. · Expires Mar 6, 2045

    granted
  2. US 11834444

    Processes for preparation of soluble guanylate cyclase stimulators

    Cyclerion Therapeutics, Inc. · Expires Nov 30, 2043

    granted
  3. US 11731977

    SGC stimulators

    Cyclerion Therapeutics, Inc. · Expires Aug 17, 2043

    granted
  4. US 11690828

    Treatment of CNS diseases with sGC stimulators

    Cyclerion Therapeutics, Inc. · Expires Jun 29, 2043

    granted
  5. US 11572358

    Solid forms of an sGC stimulator

    Cyclerion Therapeutics, Inc. · Expires Feb 2, 2043

    granted
  6. US 11466015

    Crystalline forms of 8-(2-fluorobenzyl)-6-(3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)imidazo[1,2-a]pyrazine as sGC stimulators

    Cyclerion Therapeutics, Inc. · Expires Oct 6, 2042

    granted
  7. US 11389449

    Treatment of metabolic syndrome with an sGC stimulator

    Cyclerion Therapeutics, Inc. · Expires Jul 14, 2042

    granted

Related coverage

Frequently asked questions

What is US patent 11357777?

US 11357777 (Use of sGC stimulators for the treatment of nonalcoholic steatohepatitis (NASH)) is held by Cyclerion Therapeutics, Inc.. Status: granted. Granted Jun 14, 2022. Expires Jun 9, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 11357777?

Cyclerion Therapeutics, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 17 pharmaceutical patents for this assignee.

When does US 11357777 expire?

Our index shows an expiration date of Jun 9, 2042 (16 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.